In clinical settings, the oncolytic vector talimogene laherparepvec (T-vec), a herpes simplex virus type-1 armed with an expression cassette of granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance antitumor immunity, has been used to treat patients with advanced melanoma in a phase III study [118]. This evidence concerns the gene CSF2 and melanoma.